Tezepelumab
- Generic Name
- Tezepelumab
- Brand Names
- Tezspire
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1572943-04-4
- Unique Ingredient Identifier
- RJ1IW3B4QX
- Background
Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling. Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes....
- Indication
Tezepelumab is indicated as an add-on maintenance treatment for patients aged 12 years and older with severe asthma. In Europe, it is reserved for patients who are inadequately controlled despite maintenance treatment with high-dose inhaled corticosteroids plus another drug.
...
- Associated Conditions
- Severe Asthma
- Associated Therapies
- -
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 287
- Registration Number
- NCT05329194
- Locations
- 🇺🇸
Research Site, Vancouver, Washington, United States
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 306
- Registration Number
- NCT05274815
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT05062759
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 251
- Registration Number
- NCT03809663
- Locations
- 🇺🇸
Clinical Science Institute, Santa Monica, California, United States
🇺🇸J Woodson Dermatology and Associates, Henderson, Nevada, United States
ðŸ‡ðŸ‡ºCRU Hungary Kft, Miskolc, Hungary
Effects of Anti-TSLP in Patients With Asthma
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Celeste Porsbjerg
- Target Recruit Count
- 40
- Registration Number
- NCT02698501
- Locations
- 🇩🇰
Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT01913028
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Japan
🇯🇵Kyushu Clinical Pharmacology Research Clinic, Medical Co. LTA, Fukuoka, Hakata, Japan
Safety Study of Tezepelumab (AMG 157) in Healthy Adults
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 49
- Registration Number
- NCT00972179
Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 78
- Registration Number
- NCT00757042
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.